. 2023 Jul 21;330(8):766–768. doi: 10.1001/jama.2023.13628

Table 2. Association Between Month of Treatment and Use of Mifepristone Plus Misoprostol.

	Received mifepristone plus misoprostol, %		Risk ratio (99% CI)^a
	Before release of ACOG guideline (or 2016)	After release of ACOG guideline (or 2020)	Risk ratio (99% CI)^a
All states
Month of treatment	0.40	2.50	1.04 (1.03-1.06)^b
Release of the ACOG guideline	0.54	1.78	3.20 (2.22-4.61)^c
Unrestricted states ^d
Month of treatment	0.51	3.08	1.04 (1.03-1.06)^b
Release of the ACOG guideline	0.67	2.21	3.20 (2.22-4.63)^c

Abbreviation: ACOG, American College of Obstetricians and Gynecologists.

^{^a}

P<.001 for all comparisons.

^{^b}

Per month increase after release of the ACOG guideline.

^{^c}

Increase after release of the ACOG guideline.

^{^d}

The 11 excluded states with restrictions on abortion care for fully insured private plans as of May 1, 2022, were Idaho, Indiana, Kansas, Kentucky, Michigan, Missouri, Nebraska, North Dakota, Oklahoma, Texas, and Utah.